A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
Latest Information Update: 15 May 2025
At a glance
- Drugs Bexotegrast (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms BEACON-IPF
- Sponsors Pliant Therapeutics
Most Recent Events
- 08 May 2025 According to a Pliant Therapeutics media release, the trial is currently enrolling the fourth of five potential cohorts,
- 08 May 2025 According to a Pliant Therapeutics media release, activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025
- 01 May 2025 According to a Pliant Therapeutics media release, company expects topline data from the BEACON-IPF trial to be available in the second quarter of 2025.